Pharsight

Venclexta patents expiration

VENCLEXTA's oppositions filed in EPO
VENCLEXTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546399 ABBVIE Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Jun, 2031

(7 years from now)

US10730873 ABBVIE Salts and crystalline forms of an apoptosis-inducing agent
Nov, 2031

(7 years from now)

US8722657 ABBVIE Salts and crystalline forms of an apoptosis-inducing agent
Jan, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174982 ABBVIE Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
May, 2030

(5 years from now)

US11369599 ABBVIE Melt-extruded solid dispersions containing an apoptosis-inducing agent
May, 2032

(7 years from now)

US11110087 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(9 years from now)

US9539251 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(9 years from now)

US11413282 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

US11590128 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

US10993942 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

Venclexta is owned by Abbvie.

Venclexta contains Venetoclax.

Venclexta has a total of 10 drug patents out of which 0 drug patents have expired.

Venclexta was authorised for market use on 11 April, 2016.

Venclexta is available in tablet;oral dosage forms.

Venclexta can be used as treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, treatment of aml by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine to adults 75 years or older or having certain comorbidities per a dose ramp-up including an initial 100 mg or a final 400 mg per day dose, treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer, treatment of adults with relapsed, refractory or previously untreated chronic lymphocytic leukemia including a dose ramp-up and in combination with obinutuzumab in multiple 28-day dosing cycles followed by administration in absence of obinutuzumab, treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week, treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose.

Drug patent challenges can be filed against Venclexta from 11 April, 2020.

The generics of Venclexta are possible to be released after 06 September, 2033.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-185) Jun 08, 2025
Orphan Drug Exclusivity(ODE-211) Nov 21, 2025
Orphan Drug Exclusivity(ODE-239) May 15, 2026
New Chemical Entity Exclusivity(NCE) Apr 11, 2021
Orphan Drug Exclusivity(ODE) Apr 11, 2023
New Indication(I-789) Nov 21, 2021
New Indication(I-795) May 15, 2022
M(M-265) Oct 16, 2023
Orphan Drug Exclusivity(ODE-114) Apr 11, 2023
M(M-228) Jun 08, 2021
New Indication(I-782) Jun 08, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using VENETOCLAX ingredient

NCE-1 date: 11 April, 2020

Market Authorisation Date: 11 April, 2016

Treatment: Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that p...

Dosage: TABLET;ORAL

How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage

VENCLEXTA family patents

Family Patents